Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed relapsed or refractory grade I, II, or III non-Hodgkin's lymphoma (NHL), including follicular, small lymphocytic, or marginal zone/MALT lymphoma
• •Previously treated with radiotherapy, immunotherapy, and/or chemotherapy for NHL
• •* Progression of disease or no response since last treatment for NHL
• •1D10+ lymphoma by immunohistochemistry or flow cytometry
• •Bidimensionally measurable disease at least 2 cm in a single dimension
• •No CNS metastases
• •Circulating tumor cells no greater than 5,000/mm\^3
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •ECOG 0-2
• •Life expectancy:
• •At least 3 months
• •Hematopoietic:
• •Platelet count at least 75,000/mm\^3 (unless disease related)
• •Neutrophil count at least 1,000/mm\^3 (unless disease related)
• •Hemoglobin greater than 8.0 g/dL
• •Hepatic:
• •Bilirubin less than 2.5 mg/dL
• •SGOT less than 4 times upper limit of normal
• •Renal:
• •Creatinine less than 2.5 mg/dL
• •Cardiovascular:
• •No clinically significant cardiac disease (New York Heart Association class III or IV)
• •No evidence of myocardial infarction or cardiac arrhythmia (unless surgically repaired) within the past 6 months
• •Pulmonary:
• •No clinically significant pulmonary disease
• •Other:
• •No other malignancy within the past 2 years except non-melanoma skin cancer or carcinoma in situ
• •No significant psychiatric or CNS impairment
• •No active serious infection
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 1 month after study
• •Negative anti-Hu1D10 antibody response (HAHA/HAMA)
• •HIV negative
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •See Disease Characteristics
• •At least 4 weeks since prior interferon therapy
• •At least 3 months since prior immunotherapy
• •No prior monoclonal antibody Hu1D10
• •Chemotherapy:
• •See Disease Characteristics
• •At least 4 weeks since prior cytotoxic chemotherapy
• •Endocrine therapy:
• •At least 4 weeks since prior corticosteroids (more than 10 mg prednisone/day)
• •No concurrent corticosteroids at more than 10 mg prednisone/day for pre-existing diseases or adverse reactions
• •Radiotherapy:
• •See Disease Characteristics
• •At least 4 weeks since prior external beam radiotherapy
• •At least 3 months since prior radioimmunotherapy
• •Surgery:
• •Not specified
• •Other:
• •No other concurrent lymphoma therapy